DNA mismatch repair proficiency executing 5-fluorouracil cytotoxicity in colorectal cancer cells

Cancer Biology and Therapy

Volumn 12, Issue 8, 2011, Pages 756-764

  Iwaizumi, Moriya ^a   Stephanie, Tseng Rogenski ^a   Carethers, John M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

5 FU; Colorectal cancer; Heteroduplex plasmid; Mismatch repair system

Indexed keywords

DNA; FLUOROURACIL; HETERODUPLEX; PROTEIN MLH1; PROTEIN MSH6;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; CELL STRUCTURE; CLONOGENIC ASSAY; COLORECTAL CANCER; CONTROLLED STUDY; DNA TRANSFECTION; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; MISMATCH REPAIR; PLASMID;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DNA MISMATCH REPAIR; DNA, NEOPLASM; DNA-BINDING PROTEINS; FLUOROURACIL; HCT116 CELLS; HUMANS; NUCLEAR PROTEINS; PLASMIDS; TRANSFECTION;

EID: 80054110823     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.12.8.17169     Document Type: Article

References (34)

1. Laurie JA, Moertel CG, Fleming TR, Wieand HS, Leigh JE, Rubin J, et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 1989; 7:1447-56; PMID:2778478.
2. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322:352-8; PMID:2300087; DOI:10.1056/ NEJM199002083220602.
3. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995; 122:321-6; PMID:7847642.
4. Boland CR, Sinicrope FA, Brenner DE, Carethers JM. Colorectal cancer prevention and treatment. Gastroenterology 2000; 118:115-28; PMID:10868902; DOI:10.1016/S0016-5085(00)70010-2.
5. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. J Clin Oncol 1998; 16:301-8; PMID:9440757.
6. Carethers JM, Chauhan DP, Fink D, Nebel S, Bresalier RS, Howell SB, et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 1999; 117:123-31; PMID:10381918; DOI:10.1016/ S0016-5085(99)70558-5.
7. Tajima A, Hess MT, Cabrera BL, Kolodner RD, Carethers JM. The mismatch repair complex hMutS alpha recognizes 5-fluorouracil-modified DNA: implications for chemosensitivity and resistance. Gastroenterology 2004; 127:1678-84; PMID:15578504; DOI:10.1053/j.gastro.2004.10.001.
8. Meyers M, Wagner MW, Mazurek A, Schmutte C, Fishel R, Boothman DA. DNA mismatch repair-dependent response to fluoropyrimidine-generated damage. J Biol Chem 2005; 280:5516-26; PMID:15611052; DOI:10.1074/jbc.M412105200.
9. Fischer F, Baerenfaller K, Jiricny J. 5-Fluorouracil is efficiently removed from DNA by the base excision and mismatch repair systems. Gastroenterology 2007; 133:1858-68; PMID:18054558; DOI:10.1053/j.gastro. 2007.09.003.
10. Carethers JM, Smith EJ, Behling CA, Nguyen L, Tajima A, Doctolero RT, et al. Use of 5-fluorouracil and survival in patients with microsatelliteunstable colorectal cancer. Gastroenterology 2004; 126:394-401; PMID:14762775; DOI:10.1053/j.gastro. 2003.12.023.
11. Jover R, Zapater P, Castells A, Llor X, Andreu M, Cubiella J, et al. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur J Cancer 2009; 45:365-73; PMID:18722765; DOI:10.1016/j.ejca.2008.07.016.
12. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatelliteinstability status as a predictor of benefit from fluorouracil- based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349:247-57; PMID:12867608; DOI:10.1056/NEJMoa022289.
13. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010; 28:3219-26; PMID:20498393; DOI:10.1200/JCO.2009.27.1825.
14. Liu A, Yoshioka K, Salerno V, Hsieh P. The mismatch repair-mediated cell cycle checkpoint response to fluorodeoxyuridine. J Cell Biochem 2008; 105:245-54; PMID:18543256; DOI:10.1002/jcb.21824.
15. Chung H, Chaudhry J, Lopez CG, Carethers JM. Cyclin E and histone H3 levels are regulated by 5-fluorouracil in a DNA mismatch repair-dependent manner. Cancer Biol Ther 2010; 10:1147-56; PMID:20930505; DOI:10.4161/cbt.10.11. 13447.
16. Sambrook J, Russell DW. Working with bacteriophage M13 vector. In: Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press 2001; 3:1-52.
17. Jiricny J. The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol 2006; 7:335-46; PMID:16612326; DOI:10.1038/nrm1907.
18. Hewish M, Lord CJ, Martin SA, Cunningham D, Ashworth A. Mismatch repair deficient colorectal cancer in the era of personalized treatment. Nat Rev Clin Oncol 2010; 7:197-208; PMID:20177404; DOI:10.1038/nrclinonc.2010.18.
19. Zhou B, Dong Q, Ma R, Chen Y, Yang J, Sun LZ, et al. Rapid isolation of highly pure single-stranded DNA from phagemids. Anal Biochem 2009; 389:177-9; PMID:19348781; DOI:10.1016/j.ab.2009.03.044.
20. Yamane A, Shinmura K, Sunaga N, Saitoh T, Yamaguchi S, Shinmura Y, et al. Suppressive activities of OGG1 and MYH proteins against G:C to T:A mutations caused by 8-hydroxyguanine but not by benzo[a]pyrene diol epoxide in human cells in vivo. Carcinogenesis 2003; 24:1031-7; PMID:12807753; DOI:10.1093/carcin/ bgg056.
21. Thomas DC, Roberts JD, Kunkel TA. Heteroduplex repair in extracts of human HeLa cells. J Biol Chem 1991; 266:3744-51; PMID:1995629.
22. Holmes J Jr, Clark S, Modrich P. Strand-specific mismatch correction in nuclear extracts of human and Drosophila melanogaster cell lines. Proc Natl Acad Sci USA 1990; 87:5837-41; PMID:2116007; DOI:10.1073/pnas.87.15.5837.
23. Stoklosa T, Poplawski T, Koptyra M, Nieborowska- Skorska M, Basak G, Slupianek A, et al. BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations. Cancer Res 2008; 68:2576- 80; PMID:18413724; DOI:10.1158/0008-5472. CAN-07-6858.
24. Lei X, Zhu Y, Tomkinson A, Sun L. Measurement of DNA mismatch repair activity in live cells. Nucleic Acids Res 2004; 32:100; PMID:15249596; DOI:10.1093/nar/gnh098.
25. Sunaga N, Kohno T, Shinmura K, Saitoh T, Matsuda T, Saito R, et al. OGG1 protein suppresses G:C→T:A mutation in a shuttle vector containing 8-hydroxyguanine in human cells. Carcinogenesis 2001; 22:1355-62; PMID:11532855; DOI:10.1093/carcin/22.9.1355.
26. Modrich P, Lahue R. Mismatch repair in replication fidelity, genetic recombination and cancer biology. Annu Rev Biochem 1996; 65:101-33; PMID:8811176; DOI:10.1146/annurev.bi.65.070196.000533.
27. Meyers M, Hwang A, Wagner MW, Bruening AJ, Veigl ML, Sedwick WD, et al. A role for DNA mismatch repair in sensing and responding to fluoropyrimidine damage. Oncogene 2003; 22:7376-88; PMID:14576845; DOI:10.1038/sj.onc.1206941.
28. Sowers LC, Eritja R, Kaplan B, Goodman MF, Fazakerly GV. Equilibrium between a wobble and ionized base pair formed between fluorouracil and guanine in DNA as studied by proton and fluorine NMR. J Biol Chem 1988; 263:14794-801; PMID:3170564.
29. Kremer AB, Mikita T, Beardsley GP. Chemical consequences of incorporation of 5-fluorouracil into DNA as studied by NMR. Biochemistry 1987; 26:391-7; PMID:3828314; DOI:10.1021/bi00376a009.
30. Santi DV. Perspective on the design and biochemical pharmacology of inhibitors of thymidylate synthetase. J Med Chem 1980; 23:103-11; PMID:6987403; DOI:10.1021/jm00176a001.
31. Yang G, Scherer SJ, Shell SS, Yang K, Kim M, Lipkin M, et al. Dominant effects of an Msh6 missense mutation on DNA repair and cancer susceptibility. Cancer Cell 2004; 6:139-50; PMID:15324697; DOI:10.1016/j.ccr.2004.06.024.
32. Lin DP, Wang Y, Scherer SJ, Clark AB, Yang K, Avdievich E, et al. An Msh2 point mutation uncouples DNA mismatch repair and apoptosis. Cancer Res 2004; 64:517-22; PMID:14744764; DOI:10.1158/0008-5472.CAN-03-2957.
33. Muggia FM, Peters GJ, Landolph JR Jr. XIII International Charles Heidelberger Symposium and 50 Years of Fluoropyrimidines in Cancer Therapy Held on september 6 to 8, 2007 at New York University Cancer Institute, Smilow Conference Center. Mol Cancer Ther 2009; 8:992-9; PMID:19417150; DOI:10.1158/1535-7163.MCT-08-0731.
34. Igoucheva O, Alexeev V, Yoon K. Differential cellular responses to exogenous DNA in mammalian cells and its effect on oligonucleotide-directed gene modification. Gene Ther 2006; 13:266-75; PMID:16177821; DOI:10.1038/sj.gt. 3302643.